Drug Information: Galiximab is a chimeric human-macaque anti-CD80 monoclonal antibody which targets B-cells, including malignant cells. Blocking this site with antibodies appears to produce a range of anti-cancer effects. It is taken intravenously, weekly for four weeks.
Showing posts with label Galiximab. Show all posts
Showing posts with label Galiximab. Show all posts
Wednesday, January 5, 2011
Subscribe to:
Posts (Atom)